Biotech Co.* (Symbol) | Pharma Co. (Symbol/Country) | Product | Disclosed Funding ($M) | Terms/Details (Date) |
AltaRex Corp. (Canada;TSE:AXO) | Genesis Pharma SA (member of MSJ Group [Greece]) | Altarex's OvaRex and other antibody-based immunotherapeutic cancer products | ND | Genesis gains rights to market the products in Greece, Turkey, Cyprus and the Balkans; AltaRex will supply the antibody for clinical study; Genesis will provide infrastructure for distribution and billing purposes and cover all remaining costs associated with regulatory approval in the region; resulting profits will be distributed equally to all parties (6/00) |
AltaRex Corp. (Canada; TSE:AXO) | Medison Pharma (Israel) | AltaRex's OvaRex and other antibody-based cancer therapeutics | ND | Companies created a joint venture for commercialization in Israel and the Middle East; AltaRex will supply the antibody for clinical study in Irael both before and after U.S. approval; Medison will provide infrastructure for distribution and billing purposes; and will be responsible for local drug development costs; resulting profits from commercialization will be distributed equally (7/00) |
Athersys Inc.* | Covance | Undisclosed therapeutic protein Biotechnology Services Inc. (subsidiary of Covance Inc. [NYSE:CVD]) | ND | Covance will manufacture bulk product for preclinical and clinical studies (6/00) |
Axiom Biotechnologies* | Biacore International (Sweden; BCOR) | Biacore will distribute Axiom's new high-through-put pharmacology system, HT-PS 100, on a worldwide | $4 | Biacore made an equity investment of $4M in Axiom; Biacore has been granted an option to increase its stake in the company at a predetermined price; the agreement includes co-promotion rights to selected cell lines developed by Axiom and an option for Biacore to license Axiom's multi-channel, high-throughput system HT-PS Ultra (5/00) |
Cell Pathways Inc. (CLPA) | Aventis Pharmaceuticals Inc. (unit of Aventis SA, France; NYSE:AVE) | Aventis' Nilandron for treatment of advanced prostate prostate cancer | ND | Cell Pathways gained rights to market Nilandron to urologists in the U.S. and Puerto Rico; Cell Pathways will receive a percentage of sales (7/00) |
Cell Pathways Inc (CLPA) | Paladin Labs (Canada; TSE:PLB) | Aptosyn (exisulind) for treatment of pre-cancerous colon polyps in patients with familial adenomatous polyposis | ND | Paladin gains exclusive rights in Canada (7/00) |
Cellomics Inc.* | Beckman Coulter Inc. (NYSE:BEC) | Cellomics' High Content Screening Technologies for drug discovery | ND | Companies will co-market Cellomics' ArrayScan II instrument and application software, HitKit Reagents and certain informatics products in North America and selected European countries; Beckman Coulter will exclusively distribute ArrayScan II and ArrayScan Kinetics Reader instruments, Cellomics Store and Cellomics Screen informatics products and will serve as sales agent for HitKit; companies will also create Cell Technology Centers of Excellence within academic and non-profit institutions and collaborate in mutual fields of interest (6/00) |
Cel-Sci Corp. (AMEX:CVM) | Bio Science Contract Production Corp. | Multikine, a natural mixture of human cytokines now in Phase II trials for head and neck cancer | ND | Companies signed a long-term agreement under which Cel-Sci's trained staff will make the product at BSC's Baltimore facility (6/00) |
Cephalon Inc. (CEPH) | Medtronic Inc. (NYSE:MDT) | Medtronic's Intrathecal Baclofen (ITB) Therapy for treatment of severe spasticity | ND | Cephalon is responsible for promoting ITB to neurologists under co-promotion agreement; Medtronic will provide training and support related to the device for ITB Therapy; agreement is for an initial one-year term, and will renew automatically unless terminated by either party (4/00) |
Chiron Corp. (CHIR) | Aventis Pasteur (unit of Aventis SA [France; NYSE: AVE]) | Menjugate (menigococcal C vaccine) and Fluad (adjuvenated influenza vaccine) | ND | Aventis will co-promote Menjugate in the UK and Ireland and distribute the product under its own label in the rest of Europe; Aventis will co-promote Fluad in Europe (7/00) |
CollaGenex Pharmaceuticals Inc. (CGPI) | Willvonsder & Marchesani Ges.m.b.H.& Co. KG (Austria) and Karr Dental Ltd. (Switzerland) | CollGenex's Periostat for periodontal diseasefor periodontal disease | ND | W&M and Karr obtained rights to market Periostat in Austria and Switzerland; both will pay fees associated with the regulatory approvals of Periostat and purchase the drug from CollaGenex via its UK subsidiary, CollaGenex International Ltd. (6/00) |
ICN Pharmaceuticals Inc. (NYSE:ICN) | Eli Lilly and Co. (NYSE:LLY) | Cesamet (nabilone) for management of severe nausea and vomiting associated with cancer chemotherapy | ND | ICN will market and distribute Cesamet in Canada (6/00) |
Kos Pharmaceuticals (KOSP) | DuPont Pharmaceuticals Co. Inc. (unit of DuPont [NYSE:DD]) | Development collaboration focuses on the commercialization of Nicostatin, a single-tablet formulation that integrates all the benefits of Niaspan (proprietary formulation of niacin) with a statin | $80 | KOS received $20M from DuPont through an initial equity investment; Kos will receive from DuPont additional equity investments of up to $10M and a $17.5M milestone payment at the time Nicostatin is approved by the FDA; DuPont will also provide $32.5M for future development (6/00) |
Nabi (NABI) | Collaborative BioAlliance Inc. (affiliate of The Collaborative Group Ltd.) | StaphVAX (Staphylococcus aureus type 5 and type 8 capsular polysaccharide conjugate vaccine) | ND | Collaborative BioAlliance will manufacture the vaccine at its cGMP manufacturing facility in Smithfield, R.I. (5/00) |
Vivus Inc. (VVUS) | Abbott Laboratories (NYSE:ABT) | Vivus' transurethral products Muse (alprostadil) and Alibra for the treatment of erectile dysfunction | ND | Abbott gains exclusive rights for Muse and Alibra in selected markets, including Europe, Japan, Australia, New Zealand and South and Central America; Abbott has the option to co-develop and license future Vivus transurethral products in this territory (6/00) |
SkyePharma plc (UK; SKYE) | Paladin Labs Inc. | SkyePharma's DepoCyt (injectable sustained-release cytarabine) | $1 | Paladin Labs gains exclusive Canadian marketing and distribution rights for DepoCyt; SkyePharma will receive an up-front payment of $1M, additional milestone payments tied to future events and a significant share of future revenues (7/00) |
NOTES |
||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. |
||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. |
||||
ND = Not disclosed, reported and/or available |
||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board. |
||||